Human Immunodeficiency Virus Infection
Jun 24, 2025
Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular Lymphoma; Gilead’s YEZTUGO Becomes First FDA-Approved HIV Prevention with 6-Month Protection; FDA Reviewing Incyte’s OPZELURA for Pediatric Atopic Dermatitis (Ages 2–11); Archeus Technologies Receives FDA Clearance for Prostate Cancer Therapy ART-101; Cycle Pharmaceuticals’ HARLIKU Gets First FDA Approval for Alkaptonuria
Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular Lymphoma Incyte has announced that the FDA has approved MONJUVI (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This makes it the f...
Read More...
Dec 01, 2019
World AIDS Day- 2019
Every year, 1 December is celebrated as World AIDS Day. This day is dedicated to raising awareness regarding AIDS that is caused by the spread of Human immunodeficiency virus infection and grieving those who have died of the disease.
Read More...
-Agonist.png "Toll-like Receptors Agonist")
